The Australian Public's Awareness, Knowledge and Perspectives Towards Pharmacogenomics: A Nationwide Survey, and Semi‐Structured Interviews Authors: Richelle Breed, Joanne Voisey, Esther T. L. Lau, Yasmin Antwertinger, Annalese Semmler Published: 2026 ABSTRACT ABSTRACTPharmacogenomics has the potential to improve medication responses for the public; however, its adoption in clinical practice has been slow. Consumer representation and engagement are crucial for pharmacogenomics implementation, since it is their data that is central to testing. This study investigated the Australian public's awareness, knowledge, and perceptions of pharmacogenomics via a mixed‐methods approach. Firstly, a cross‐sectional survey with a nationally representative sample of 772 members of the Australian general public assessed the frequency of pharmacogenomics awareness, knowledge, perceived benefit and concern. Subsequent semi‐structured interviews with 21 members of the Australian public provided deeper insights into perceptions through thematic analysis. Over three‐quarters (76.3%) of participants were unaware of pharmacogenomics, while 6.2% categorized themselves as aware and knowledgeable about the topic. Interviews found five major themes: (1) Knowledge and Understanding, (2) Trust, (3) Personalized and Holistic Care, (4) Clinical Utility, and (5) Accessibility. Overall, participants highlighted several key steps for pharmacogenomics integration into clinical practice and to increase awareness. These include the importance of simplifying the terminology, providing education and transparency to overcome apprehension, addressing cost concerns, communicating the value clearly and increasing community engagement. Introduction Pharmacogenomics (PGx) is the study of how a person's genetic variations can influence their response to medications. Its goal is to optimize medication therapeutic response while avoiding adverse drug reactions. Although pharmacogenomics is a form of genetic testing, it differs from many other genetic tests because its primary purpose is to guide medication selection and dosing rather than diagnose inherited conditions or determine carrier status. Despite its potential benefit clinically, the implementation of pharmacogenomics into practice has been slow [1]. The implementation of pharmacogenomics into the healthcare system is contingent on multiple stakeholders. It's the consumer's genes that are collected and analyzed to generate pharmacogenomics results, consequently, it will be the consumer (i.e., the general public) who will play the decisive role to determine its overall acceptability and uptake into clinical practice. Furthermore, the underrepresentation of diverse ethnicities in genomic research has been well recognized [2, 3, 4, 5]. Australia offers a unique perspective, as one of the most culturally diverse countries in the world [6], with pharmacogenomics implementation cited to offer an extensive impact therapeutically to the population [7]. Many studies have been published that investigate the healthcare provider's perspective on pharmacogenomics, with far fewer examining the general public's stance. Pharmacogenomics awareness and knowledge among the public have been cited as reasonably low despite advocacy to grow its application [8]. In this study, awareness and knowledge represented distinct concepts: awareness simply referred to having heard of the topic previously, whereas knowledge referred to greater familiarity or comprehension. Globally, a United Kingdom representative‐sample survey found that 52% of the public understood that DNA variations could predict medication benefits and 48% recognized that DNA could indicate side effect risks [9]. Haddy et al. conducted the first Australian study exploring consumer perceptions of pharmacogenomics among individuals with, or closely connected to someone with, a chronic medical condition [10]. In their study, the researchers found that a total of two participants out of 35 (5.7%) understood the relationship between genetic profile and medication response. Subsequent studies within Australia have also analyzed selected populations such as pediatric oncology patients and their caregivers [11]. However, no study has explored the Australian public's overall stance on pharmacogenomics. This study aimed to understand the Australian public's awareness, knowledge and perceptions of pharmacogenomics. Methods Ethics Approval This study was approved by the QUT University Human Research Ethics Committee (LR 7175). Study Design and Setting The research design employed a mixed‐method, two‐phase approach. The first phase was a cross‐sectional, nationwide, online survey via Qualtrics (https://www.qualtrics.com). The second phase was semi‐structured online interviews via video conferencing (Zoom; Version 6.3) and structured around the preliminary themes identified in the survey to explore deeper insights. Phase 1: Survey Development The 54‐item survey questions ranged from binary, multiple choice, Likert scale, and open‐text options (Supporting Information). Item generation was informed by the study objectives and previous literature investigating consumer and public perspectives towards pharmacogenomics and genetics, including Australian and international studies [10, 12, 13]. The survey was designed as an exploratory instrument to provide descriptive data and inform the subsequent qualitative interview phase. Face validity testing was undertaken with 15 members of the general public to assess item clarity, relevance and appropriateness, resulting in minor revisions to wording and readability. Formal psychometric validation was not performed as the survey was not designed to measure a single latent construct or develop a new scale, but rather to capture multiple domains of awareness, knowledge and perceptions relevant to the study objectives. Participants were first asked whether they had heard of or knew about pharmacogenomics. A concise definition was then provided (Figure 1) to ensure all participants had a foundational and consistent understanding of the concept prior to responding to subsequent questions. The survey design required participants to complete all questions before submission, ensuring no missed responses were recorded. Pharmacogenomics definition provided to survey participants. Sample Recruitment and Data Collection A calculated sample size of 600 was needed to give a 95% confidence level with a 4% margin of error based on Australia's population size of 26 million in 2023 [14]. A data collection agency (the Online Research Unit (ORU)) was used to recruit participants via stratified sampling. This allowed for participants' ages, genders, and geographical locations to be representative of Australian Census data. The eligibility criteria consisted of adult participants aged 18 years and older with a validated Australian postcode. Survey data were collected from 21st November 2023 to 27th November 2023. A second method of convenience sample recruitment was omitted from the final analysis because its nonrandom design did not withstand sensitivity testing. Phase 2: Semi‐Structured Interviews Development The semi‐structured interview guide explored a fuller analysis of participants' ideas on pharmacogenomics based on preliminary survey themes (Supporting Information). Face validity testing occurred with one member of the general public and assisted the facilitator with the flow, understanding, and timing of the interview; no changes to the questions were made. Sample Recruitment and Data Collection Participants were recruited through convenience sampling using three methods: (1) advertisements through culturally diverse communities located in Queensland, Australia, (2) advertisement on Queensland University of Technology's public‐facing research participation webpage, or (3) via an expression of interest form at the end of the Phase 1 Survey. Semi‐structured interviews began in April 2024 and ended in January 2025. Interviews continued until data sufficiency (a term replacing data saturation) [15], defined as the subjective point when the dataset was judged to offer sufficient extent for analysis [16]. All discussions were facilitated by one researcher (RB), with only the participant and researcher present. Participants were aware that the researcher was conducting the research as part of their postgraduate degree. All interviews were audio‐recorded and transcribed, with field notes taken by the facilitator. Data Analysis Quantitative data analysis was performed using SPSS software (IBM, Version 29.0). Descriptive statistics were used to summarize frequencies. The qualitative data were analyzed using NVivo software (Lumivero, Release 1.7.1). Interviews were reflexively thematically analyzed using Clarke and Braun's framework [17, 18]. Data was inductively derived and coded manually by one author (R.B.), with the codebook and overall theme consensus discussed among four authors (R.B., A.S., J.V., E.L.). Participant interviews and primary analysis of the data were conducted by the first author, a PhD candidate and pharmacist. Reflexive data interpretation practices were employed, which included maintaining a reflexive journal and engaging in regular research team discussions. The drafted themes and their transcripts were reviewed by five interview participants, with their recommendations incorporated to finalize the themes. Results Phase 1: Survey At the conclusion of the survey, 781 responses were obtained. The data collection agency was unable to confirm the overall response rate; however, the company's average response rate is 11%–11.5%. Participants were excluded from the dataset because they were under 18 years (n = 8) or recorded an invalid Australian postcode (n = 1). In total, 772 responses were included for analysis. Demographics Complete survey participants' demographics are shown in Table 1. Over one‐third of the participants (37.3%) had at least one chronic medical condition and 58.3% took prescribed medicine (slightly lower than that noted by the Australian Bureau of Statistics in 2022 which recorded 50% and 68.6%, respectively [19]). Additionally, 44.2% had experienced or knew of someone who experienced an adverse effect from using medication. Of those who had or knew of someone who had experienced an adverse effect from medication, 26.1% stated that the adverse effect was serious (e.g., requiring hospitalization or medical assistance). When asked if they had ever given DNA for testing, 86.3% had not. TABLE 1Survey participant demographics (n = 772).Demographic variableFrequency (%) Age (years) 18–2473 (9.5)25–34115 (14.9)35–44182 (23.6)45–54104 (13.5)55–64102 (13.2)65–74125 (16.2)75 or older71 (9.2) Gender Male399 (51.7)Female369 (47.8)Other1 (0.1)Prefer not to say3 (0.4) State of residence New South Wales251 (32.5)Victoria214 (27.7)Queensland141 (18.3)Tasmania17 (2.2)Northern Territory6 (0.8)South Australia60 (7.8)Western Australia69 (8.9)Australian Capital Territory14 (1.8) Modified Monash Model Metropolitan areas603 (78.1)Regional centers61 (7.9)Large rural towns46 (6.0)Medium rural towns22 (2.8)Small rural towns29 (3.8)Remote communities11 (1.4) Highest level of education completed Never attended school1 (0.1)Did not complete secondary education (high school)18 (2.3)Completed year 10 schooling42 (5.4)Completed year 11 schooling13 (1.7)Completed year 12 schooling83 (10.8)Diploma or certificate‐level qualifications207 (26.8)Bachelor level qualifications260 (33.7)Postgraduate level qualifications148 (19.2) Born in Australia Yes565 (73.2)No207 (26.8) English as a preferred language Yes746 (96.6)No26 (3.4) Studied genetics at a school of university level Yes147 (19.0)No625 (81.0) Work or previous work in a health‐related occupation Yes78 (10.1)No694 (89.9) Survey participant demographics (n = 772). Pharmacogenomics Awareness and Knowledge Most participants (76.3%) reported that they had neither heard of nor were knowledgeable about pharmacogenomics. Followed by 17.5% that had heard of the term pharmacogenomics; however, did not know what it was. Lastly, 6.2% had heard of and were knowledgeable about the topic. The sample characteristics for each response subsample are shown in the Supporting Information (Table S1). Pharmacogenomics' Perceived Benefits and Concerns Most participants saw pharmacogenomics as mostly beneficial (39.4%) or highly beneficial (33.8%). Thereafter, participants rated pharmacogenomics as limited benefit (12.7%), not sure (10%), or of no benefit (4.1%). When asked about their concerns about pharmacogenomics in clinical practice, most participants were not concerned (74.1%). Therefore, 25.9% were concerned to some degree and an open‐text box gathered the participants' concerns. Preliminary themes observed from open‐text responses included mistrust, finances, misuse, questioning the validity and lack of education. Willingness to Undertake Pharmacogenomics for Specific Medical Conditions Participants' willingness to undertake pharmacogenomics varied depending upon the medical condition being managed (i.e., high cholesterol, depression or cancer). For participants' willingness to undergo pharmacogenomic testing for high cholesterol and depression, similar results were obtained, 65.3% and 64.8%, respectively. However, the participant's willingness to undergo pharmacogenomics testing increased to 80.6% if the data assisted cancer treatment. Phase 2: Semi‐Structured Interviews Demographics Twenty‐one participants were interviewed. The median age of participants was 33 years (range = 19–71 years). No participant had undergone prior pharmacogenomics testing, and most participants were unaware of pharmacogenomics before this project (66.7%). Further participant demographic information is given in Table 2. TABLE 2Semi‐structured interview participant demographics (n = 21).Demographic variableFrequency (%) Age (years) 18–244 (19.05)25–347 (33.33)35–446 (28.57)45–541 (4.76)55–641 (4.76)65–742 (9.52)75 or older0 (0) Gender Male4 (19.05)Female16 (76.19)Other0 (0)Prefer not to say1 (4.76) State New South Wales1 (4.76)Victoria3 (14.29)Queensland17 (80.95) Highest level of education completed Never attended school0 (0)Did not complete secondary education (high school)0 (0)Completed year 10 schooling0 (0)Completed year 11 schooling0 (0)Completed year 12 schooling1 (4.76)Diploma or certificate‐level qualifications0 (0)Bachelor level qualifications16 (76.19)Postgraduate level qualifications4 (19.05) Born in Australia Yes10 (47.62)No: self‐reported country of birth included Afghanistan, Canada, China, Iraq, Malaysia, Myanmar, New Zealand, South Africa and Zimbabwe11 (52.38) English as a preferred language Yes13 (61.90)No8 (38.10) Prescribed medications Yes7 (33.33)No14 (66.67) Chronic illness or disability (multiple items could be selected) Arthritis1 (4.76)Back pain1 (4.76)Asthma or lung condition2 (9.52)Cancer1 (4.76)Depression or anxiety6 (28.57)Other: self‐reported chronic illness or disability included sleep apnea, autism, ADHD, POTS and post‐polio4 (19.05)None9 (42.86) Studied genetics at a school of university level Yes8 (38.10)No13 (61.90) Work or previous work in a health‐related occupation Yes5 (23.81)No16 (76.19) Semi‐structured interview participant demographics (n = 21). Eight participants were recruited through culturally diverse community networks, seven via Queensland University of Technology research webpage advertisement, and six participants responded after being contacted through the expression of interest from the former survey. The average interview length was approximately 43 min (range = 30–56 min). Five themes were constructed from the interviews: (1) Knowledge and Understanding, (2) Trust, (3) Personalized and Holistic Care, (4) Clinical Utility, and (5) Accessibility; shown in Table 3 with their respective participant quotes. TABLE 3Themes and corresponding participant quotations.Theme One: Knowledge and UnderstandingImportance of having education and information on the topic “Sometimes the reluctance comes from not having all the information.” [Interview 9] “I'm working—I'm at the moment [a] health educator. I do follow lots of projects. That's why I found out it takes time. The more you give the education and information, the better and people against, accept it.” [Interview 5] Complex terminology “I didn't actually know how to read it, to be honest.” [Interview 13] “Sorry, can you say the word again, just because I'm going to pronounce it wrong?” [Interview 2] “Do you think—I'm just gonna call it ‘pharma’—do you think that it can show how much your body can handle?” [Interview 10] “I did think about medication just from the pharma perspective. The genomics, I'm less familiar with the use of that word, so in my head I was thinking I would be able to associate it more with pharmacogenetics or pharmacogenes, or something like that, but not genomics. So, it wasn't very apparent to me at the start.” [Interview 1] Difficulty translating the term to non‐English languages “The meaning of the pharmacogenetics you can't translate, I know, but the meaning or simple English for what is pharmacogenetics, that kind of thing. And another thing, one thing is that, how many people come to live in Australia? You think about that.” [Interview 5] Theme Two: TrustHistorical injustices and genetic discrimination “I'm Māori, I'm Indigenous, you know what I mean? So we have a really fraught relationship with our information being used and abused and exploited. So I'm just like … what are the implications that I don't know about, you know?” [Interview 8] Trust for Australia in comparison to other countries “Yes, it's better in Australia. In terms of laws and you know how you all handle things. Most of the government agency, police, you know, healthcare, … even your research … you tell us about private and confidentiality, how you collect the data, you know, what are you going to use our data for, you know, it's very clear.” [Interview 14] Distrust in the private sector “You've got big pharma who are big, who are just very ready to push chemical use into our bodies just for their own benefits, and I think there's just some awful disadvantages with that approach.” [Interview 16] Trust health professionals' or friends' recommendation “…some of the families here, they have a good strong relationship with their GPs … I've been in the country [several] years now, and my GP is my number one, like a source of information if I needed to, to have any questions about me.” [Interview 6] “If it's coming from someone that I know, that I trust, who has benefited from it, that's going to be much more impactful.” [Interview 8] The impact of the COVID‐19 pandemic on people's perception of healthcare “I feel like people hear the word [pharmacogenomics], shut off, have their ideas in their head already based on preconceived ideas which a lot of people have especially after COVID.” [Interview 2] “I think for every community, COVID was like a big lack of trust from the government and then there's a lot of suspicion of the medical field.” [Interview 7] “I just would imagine that a lot of the things would be, sort of post‐COVID, you know, those same sort of concerns that people have about who's benefiting, who's making money off my DNA … that's still kind of out there.” [Interview 8] DNA privacy “My main concern is just hopefully that institutions, even if I do genetic testing, it won't be passed on to other places, they won't use it for other projects. … I just want more transparency when I get genetic testing.” [Interview 20] “Aside from the cost, I don't have too many [concerns] because while I realize that different companies may use it for either—some might use it for medical research, and some might use it for more financial gain. I don't really mind as long as I'm getting a net positive from it. Because, I mean, if I'm getting a lot out of it and they want to use that data, I'm not against it because I am getting something from it.” [Interview 2] “I think it should be treated, you know, as important as, you know, your bank information, your personal details. It's like the key to your house, it's like your address.” [Interview 19] “But if you really think about it like, how much can someone really do with that information that's gonna affect you, right? So I think it's more so the idea of big companies having your information, but then you have to like think specifically, right? Like what type of information do they have and it's not like it's your bank information, right? That's gonna have more of an impact than … yeah.” [Interview 18] Previous large‐scale privacy breaches “There was a big 23andMe scandal, which isn't quite the same thing, but it was, like, your data is just getting sent off and sent to anyone.” [Interview 21] Theme Three: Personalized and Holistic CareHolistic care “I think I see pharmacogenomics as being one tool in the toolkit” [Interview 4] Holistic care considerations of lifestyle management, complementary/herbal/non‐Western medicine and/or spiritual implications “I also equally believe that, if there's a way for patients to get better without having to take drugs, I think that's equally important as well. So I would, − this is my personal opinion—but I would much prefer not to have to take medications so I can do some lifestyle changes because there's always side effects when you're taking new drugs [or] just anything that goes in your body.” [Interview 20] “We have our traditional Chinese doctor, so every time when I was sick, the first thing I actually seek help is not from GP it's usually from my Chinese traditional doctor because we have different ways to see the disease.” [Interview 11] “I guess more just like even Chinese or Indian medicine or naturopathy or diet, kind of using food as medicine or I guess something that wasn't instantly just going to be a band‐aid pharmaceutical would be my preference” [Interview 17] “I think it just makes me think of like that being such an important thing to, like, a lot of Pasifika people. There'd be questions of like, ‘What are the spiritual implications of me getting this testing?’” [Interview 7] Associating medications with toxins or chemicals “I hate that I have to take these medications because they're very strong and it's chemicals inside of me.” [Interview 16] Theme Four: Clinical UtilityQuestioned the potential reliability and predictive certainty “But if there's a shortage of that medication then you can't just rely on the pharmacogenomic test because maybe having something that's suboptimal but actually you can get is a better option than something that's great but actually you can only get it at this one obscure pharmacy ages away from you” [Interview 4] “Having had polio, there was a fair amount of experimentation [that] went on because people were faced with an epidemic that—or a pandemic that was, you know, unknown in terms of Australia particularly. So, I think there's some care to be taken … just holding that line between helping people or using people. I don't think it's ever intentional, but that has impacts on people, if that's just going to be used that way. And I think that might be a concern for the general public is—you know, are people being used as guinea pigs.” [Interview 9] Questioned the significance of pharmacogenomics “I wouldn't say it's not urgent, like I feel like it is necessary. But the level of urgency I'm not sure of.” [Interview 15] “But then the average person is like, oh, okay, if it's only going to improve my life by five per cent and it's going to be unnoticeable, why would I bother?” [Interview 7] Severity of a medical condition, poor medication or healthcare experiences would influence pharmacogenomics uptake “I've had enough illness in my life and experience that I would, you know, I would definitely reach out for anything that would improve the way things are done.” [Interview 9] “I'm only really newly diagnosed, … whereas, you know, there's some people online that have been struggling for, you know, years and years and years trying to get the right dose of medication. So I suppose the longer that this goes for me, looking for an effective solution, the higher the likelihood that I am to engage with pharmacogenomics.” [Interview 8] Theme Five: AccessibilityCost's effect on the adoption of pharmacogenomics “The average person probably wouldn't think too deeply into where does my information go afterwards? They're more just concerned about [feeding] themselves. Yeah, I think cost would probably be the biggest barrier.” [Interview 3] “[If] it's not backed by Medicare, I think it sounds—It's lost on me pretty much. Just financially, from a financial standpoint. Cause it does sound like one of those things that would have a bit of a price tag” [Interview 19] “It's sort of low income people that feel like they don't have a voice. So I would expect that that's gonna continue on with this pharmacogenomics sort of thing.” [Interview 8] Assumed pharmacogenomics testing would be expensive “I'm just thinking like why isn't this used more, but then I kind of think it's probably really expensive” [Interview 10] “I'm not sure about the cost of this pharmacogenomic, which I think is expensive, that's why it's not so easily available.” [Interview 14] “I think it's a really clever idea. I think it's something which absolutely should be pursued. The one thing on my mind would be, I guess, the financial side. Who flips that bill? Is that the medical provider or Medicare or something? Or do you have to pay a gap or the entire thing? Because I am sure—well, not sure, but I'm assuming it's quite intensive, both looking at the gene and all the lab work and pathology part.” [Interview 2] Themes and corresponding participant quotations. Theme One: Knowledge and Understanding Knowledge and, hence, education were recognized as essential for raising awareness and understanding (which could also foster openness) about pharmacogenomics among the public. A major initial barrier to understanding and engaging with the topic was the term itself, pharmacogenomics. It was seen as complex, requiring the word to be dissected to grasp the general concepts. Some participants found it difficult to pronounce and would hesitate or avoid pronouncing the word. A couple of linguistically diverse participants also noted the difficulty of translating the term “pharmacogenomics” into non‐English languages. One participant also highlighted the need to simplify this terminology because of Australia's multiculturalism and the range of spoken languages. It was noted that it would be beneficial to clarify the differences between pharmacogenomics testing and genetic testing, especially since pharmacogenomics testing cannot diagnose a condition (a common misconception noticed in the interview at times). Additionally, some participants found it helpful to understand that pharmacogenomics testing examines only specific regions of the DNA, not the entire genome. One participant highlighted the benefits of pharmacogenomics testing in comparison to genetic testing, noting that it is “lower stakes” due to the accessibility through a doctor or pharmacist, compared to a genetic test which would involve a genetic specialist. Another participant expressed specific interest in how the test works and whether pharmacogenomic results could apply to relatives (or similar genetic groups), as this information would also influence their decision to undergo testing due to its potential wider benefits. Only one participant who was aware of pharmacogenomics stated that they found enough education on the topic. Theme Two: Trust Throughout the interviews, trust was a recurring theme among participants. Participants' levels of trust in the Australian Government varied widely. Some participants highlighted their concern, due to the historical injustices and genetic discrimination experienced by Indigenous peoples (inclusive of First Nation Australians, Māori and Pasifika) about the potential for further genetic discrimination. A couple of participants who immigrated to Australia expressed greater trust in the Australian government in comparison to their country of origin. In general, there was distrust in the private sector, with specific concern about companies such as insurance corporations and “big pharma” (i.e., major pharmaceutical companies) managing pharmacogenomics data due to their potential power and influence. A couple of participants indicated that they would trust pharmacogenomics recommendations to a greater degree if it specifically came from people known to them, such as trusted health professionals or friends. The impact of the COVID‐19 pandemic and how it was handled was a common observation among some participants' current perception of healthcare. Particularly, the heightened distrust and suspicion towards health advice among the Australian population, especially for marginalized communities, was underscored by a participant. For pharmacogenomics, participants reported concerns others might have regarding DNA that arose after COVID‐19, which in part was intensified by misinformation about mRNA vaccines. Finally, an emphasis was placed on the importance of transparency in reducing mistrust and fear, particularly to help address people's fear of the unknown about the topic. Sub‐Theme: Privacy A significant point of contrast among participants was the concern over DNA data privacy and genetic exceptionalism (the idea that genetic information should be handled differently from other medical or personal data). Some participants highlighted the potential for DNA to be exploited (whether through improper data access, storage or management), and stressed the importance of DNA privacy, with one participant emphasizing it as more important than bank information. Other participants were unsure how exploitation could occur or were unconcerned by this possibility. Interestingly, a separate participant drew conflicting concerns regarding the level of security needed for genetic data versus bank details, as they perceived disclosed bank information as more damaging. Participants supported their arguments by citing publicized large‐scale privacy breaches such as Optus, Medibank, and 23andMe to either reference the need for additional caution or that data risks will always exist and maintaining complete privacy is improbable. Theme Three: Personalized and Holistic Care The ability to personalize care was identified as a benefit of pharmacogenomics, although even without pharmacogenomics, participants hoped that their care would be holistic—tailored to the whole person—including their goals, values and beliefs. Holistic care to some participants involved lifestyle management, complementary/herbal/non‐Western medicine and/or the consideration of spiritual implications rather than a reliance on medications. Furthermore, the reluctance to take medications (unnecessarily) was also apparent throughout the interviews, with several participants associating medications with toxins or chemicals. Theme Four: Clinical Utility Clinical utility refers to the likelihood that test results will inform and support clinical decisions that improve patient outcomes, that is, the usefulness of the intervention in clinical practice [20]. There were questions about the potential reliability and predictive certainty of the pharmacogenomics testing results. A subset of participants questioned the significance of pharmacogenomics. This may be because pharmacogenomics testing only examines a person's medication response, suggesting its overall utility and benefit in clinical practice as less evident. Among several participants, the severity of a medical condition (determined by the risk of immediate morbidity or mortality) would greatly influence their likelihood to undergo pharmacogenomics testing. Moreover, poor medication or healthcare experiences (e.g., knowledge or experience of long periods of ineffective medication, or previous adverse drug reactions) positively influenced some participants' views on undertaking pharmacogenomics testing. Theme Five: Accessibility Participants expressed accessibility considerations such as the influence of their geographic location, test availability and associated costs. Cost and its effect on the adoption of pharmacogenomics was considered a primary barrier for several participants. It was favored that the testing be funded through Medicare (a publicly funded scheme in Australia that covers the costs of medicines and various medical services), particularly so that individuals from lower socioeconomic backgrounds are not disadvantaged or discriminated against. Interestingly, without knowing the cost of the pharmacogenomic tests, participants assumed it would be expensive (potentially due to the nature of genetic testing), which immediately hindered their consideration to use the service. Participants' preferences regarding genetic data collection varied. Currently, DNA for pharmacogenomic testing can be collected via saliva or blood samples. Some participants regarded saliva samples as less invasive and more accessible (particularly for individuals with a fear of needles or difficult venous access); therefore aiding the widespread implementation of pharmacogenomics. Meanwhile, others believed that blood collection would yield more precise results or were undeterred since they have undertaken blood tests in the past. A third subset of participants was indifferent to the mode of DNA collection. Discussion This study comprehensively examined the Australian general public's awareness, knowledge, and perceptions of pharmacogenomics. The combination of quantitative and qualitative data allowed for a well‐rounded understanding of Australian's current stance on the topic. Overall, this study found that Australian's awareness and knowledge of pharmacogenomics remains limited at 6.2%. Education was highlighted as key to increasing awareness and understanding among the public, empowering informed decision‐making. Participants surveyed that identified as having higher education, previous genetics study at a school or university level, or employment in health‐related fields were more likely to know about pharmacogenomics. Other studies have also found that, while at times small in effect, the most significant demographic associated with increased genetic knowledge was higher education [21, 22, 23]. The first step to achieving greater education for pharmacogenomics, as evident from interview participants, is to simplify pharmacogenomics terminology. Participants found the term “pharmacogenomics” too complex, leading to reluctance to inquire about or discuss the test in the semi‐structured interviews. This would be a significant barrier to people's engagement when discussing the topic with health professionals in clinical practice. Meagher et al. reported this reluctance when participants received their pharmacogenomics results, as they rarely used technical terms such as “pharmacogenetics” or “drug‐gene interaction” [24]. Furthermore, in our study, some linguistically diverse participants highlighted that pharmacogenomics cannot be translated appropriately into their native language. This risks greater marginalization for linguistically diverse communities, especially since many are already underserved by the European‐dominated genetics dataset [4, 5]. Interestingly, the willingness to undergo pharmacogenomics testing for medication treatment was influenced by the type of diagnosed condition. This finding was first shown in the survey and later replicated in the interviews. Furthermore, almost three‐quarters of the survey participants were unconcerned about pharmacogenomics; however their willingness to undergo testing for high cholesterol and depression treatments was 65.3% and 64.8%, respectively. This could suggest that despite a person being unconcerned, the value of testing may not be apparent and will need to be clearly detailed when treating conditions seen as less severe. Trust was a key factor affecting pharmacogenomics' perception. Historical sources of distrust must be acknowledged, particularly those related to pharmaceutical and genetic research. In the Australian context, these include the impact of colonization, racism and exploitative research involving First Nation Australians and other marginalized groups. Recently, the COVID‐19 pandemic has further amplified a lack of trust in the pharmaceutical industry and heightened concerns surrounding genetics among some communities. Lessons from COVID‐19 emphasize the importance of addressing public mistrust and fostering meaningful community engagement when introducing health technologies [25]. Furthermore, Nunn et al. highlighted community involvement as essential for the equitable implementation of genomics; however, only 33% of global genomic initiatives reported such involvement [26]. Participants in the present study placed greater trust in recommendations from well‐known, trusted health professionals or friends. This trust from a familiar health professional could prove beneficial for pharmacogenomics, since it can be offered by general practitioners or pharmacists. Although, notably, it will also require greater comprehension and confidence from health professionals to apply pharmacogenomics information [27]. Financial considerations were a primary factor affecting potential uptake of pharmacogenomics among many participants. Cost as a key challenge for the public's perceived uptake of either genomics or pharmacogenomics has also been seen in other countries, such as Canada, the United Arab Emirates, and the United States [28, 29, 30]. Several participants in our study preferred that pharmacogenomics testing be financially supported by the federal government (i.e., via Medicare). Haddy et al. detailed this viewpoint, with their Australian participants also advocating for government funding of pharmacogenomics [10]. In 2010, one pharmacogenomics test was subsidized under Medicare; by 2026, only two additional tests had been included, with a fourth pending [31, 32, 33, 34]. Most pharmacogenomics tests in Australia remain consumer funded. The consumer, as the ultimate stakeholder, needs to be central to the discussions surrounding pharmacogenomics integration into clinical practice. While pharmacogenomics has the potential to improve medication outcomes, it can widen health inequalities if the lack of diversity and equity are not addressed [35]. This is particularly relevant within Australia's multicultural population. Our findings suggest that successful implementation will require more than technical readiness alone. Public awareness of pharmacogenomics remains low, highlighting the need for educational initiatives that use accessible terminology and clearly communicate both the potential benefits and limitations of testing. Participants identified trusted healthcare professionals, particularly general practitioners and pharmacists, as important sources of information, indicating that workforce education and clinician confidence will be critical to effective implementation. Concerns regarding cost and affordability also suggest that reimbursement pathways and equitable access mechanisms (including delivery models that support rural communities) will be important considerations for broader uptake. Collaborative, co‐designed approaches involving consumers throughout implementation may assist in addressing a lack of awareness and concerns regarding privacy, trust and accessibility. Together, these strategies may support both public acceptance and sustainable integration of pharmacogenomics into routine care. Limitations This study had several limitations. The survey's cross‐sectional design restricts the ability to draw causal conclusions. Potential non‐response bias arose as the data collection agency could not confirm the overall response rate; however, the company's average response rate is 11%–11.5%. The sample obtained still reflected the Australian Census data of the Australian public's ages, genders, and geographical locations. As with all qualitative studies, the findings cannot be generalized. Self‐selection bias for interview participants and the use of a single primary coder may have influenced interpretation of the data; however, reflexive journalling, team discussions and participant member checking were used to enhance reliability. While the interviews set out to ensure insights came from a breadth of people with varying backgrounds, consequently, the research did not delve deeper into specific culture's opinions. Furthermore, a key limitation is that no interview participants were of Aboriginal or Torres Strait Islander origin. This limits the study's ability to emphasize significant perspectives from First Nation Australians. We acknowledge that Indigenous voices are often underrepresented in genomics research and should be addressed appropriately in future research. Conclusion This study provides a contemporary view of the Australian public's awareness, knowledge and perspectives of pharmacogenomics. Awareness of pharmacogenomics among survey participants was low, and initial steps, as highlighted by interview participants, will need to include transparent, holistic, and relevant communication. Partnership and engagement with the general public could help develop education on pharmacogenomics that uses appropriate terminology and addresses key questions, such as the cost and unbiased value of the service. Author Contributions R.B., J.V., E.T.L.L., Y.A., and A.S. wrote the manuscript; R.B., J.V., E.T.L.L., Y.A., and A.S. designed the research; R.B. performed the research; R.B. analyzed the data. Funding This research was supported by funding from the Queensland University of Technology's Centre for Genomics and Personalized Health; R.B. is supported by the Research Training Program (RTP) Stipend Scholarship and QUT Faculty of Health Top Up Scholarship. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Appendix S1: cts70701‐sup‐0001‐Supinfo.zip.